Repligen (NASDAQ:RGEN – Free Report) had its price target lifted by JPMorgan Chase & Co. from $170.00 to $210.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. Stifel Nicolaus […]